The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

• Status: Recruiting
• Trial end date: 2022-10-28
• Target enrollment: 0
• Participant gender: All

Summary

Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incyte Corporation
• Treatments: Pembrolizumab

Criteria

Inclusion Criteria:

• Currently enrolled and receiving treatment in an Incyte-sponsored clinical study (parent protocol) of pemigatinib as monotherapy or combination therapy.

• Currently benefiting from and tolerating treatment with pemigatinib, as determined by the investigator.

• Demonstrated compliance, as assessed by the investigator, with the parent protocol requirements.

• Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures.

• Currently have no evidence of progressive disease, as determined by the investigator, following treatment with pemigatinib as monotherapy or combination therapy.

• Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

• Able to access pemigatinib commercially or outside of a clinical trial.

• Permanently discontinued from the parent protocol for any reason.

• No longer meet the inclusion/exclusion criteria from the parent protocol if still receiving treatment.

• Women who are pregnant or breastfeeding or participants expecting to conceive or father children within the projected duration of the study.